(Q38169237)

30 August 2017

Tubulin inhibitors: a patent review (English)

1 reference

30 August 2017

Yi-Min Liu

1

1 reference

30 August 2017

Hsiao-Ling Chen

series ordinal

2

1 reference

30 August 2017

Hsueh-Yun Lee

series ordinal

3

1 reference

30 August 2017

Jing-Ping Liou

series ordinal

4

1 reference

30 August 2017

language of work or name

English

0 references

publication date

9 December 2013

1 reference

Expert Opinion on Therapeutic Patents

30 August 2017

1 reference

30 August 2017

24

1 reference

30 August 2017

1

1 reference

30 August 2017

69-88

1 reference

Targeting microtubules for cancer chemotherapy

30 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Microtubule dynamics as a target in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

High-resolution model of the microtubule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

What tubulin drugs tell us about microtubule structure and dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Microtubules as a target for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Microtubules and resistance to tubulin-binding agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Vascular attack as a therapeutic strategy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Vascular targeting agents as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Vascular targeted therapies in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Microtubule-binding agents: a dynamic field of cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Molecular mechanism of action of microtubule-stabilizing anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Microtubule-binding natural products for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Tubulin-interactive natural products as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

21 January 2018

Antimitotic inhibitors

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Antimicrotubular drugs binding to vinca domain of tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Mechanism of action of tubulysin, an antimitotic peptide from myxobacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

The mechanism of action of colchicine. Colchicine binding properties of sea urchin sperm tail outer doublet tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Localization of the colchicine-binding site of tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

An overview of tubulin inhibitors that interact with the colchicine binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

The tubulin colchicine domain: a molecular modeling perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Combretastatin A4 phosphate: background and current clinical status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

AVE8062: a new combretastatin derivative vascular disrupting agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

The development of combretastatin A4 phosphate as a vascular targeting agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Anticancer strategies involving the vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Indibulin, a novel microtubule inhibitor, discriminates between mature neuronal and nonneuronal tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Structure of tubulin at 6.5 A and location of the taxol-binding site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Taxol suppresses dynamics of individual microtubules in living human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

How Taxol stabilises microtubule structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Possible binding site for paclitaxel at microtubule pores.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Microtubule active agents: beyond the taxane frontier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Role of formulation vehicles in taxane pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Discovery of ixabepilone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Beyond taxanes: the next generation of microtubule-targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Novel drugs targeting microtubules: the role of epothilones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Microtubule-stabilizing marine metabolite laulimalide and its derivatives: synthetic approaches and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Computational comparison of microtubule-stabilising agents laulimalide and peloruside with taxol and colchicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Laulimalide and paclitaxel: a comparison of their effects on tubulin assembly and their synergistic action when present simultaneously

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

The assembly-inducing laulimalide/peloruside a binding site on tubulin: molecular modeling and biochemical studies with [³H]peloruside A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Secondary and tertiary sulfonamides: a patent review (2008 - 2012).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2014.859247

Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. Production, isolation, physico-chemical and biological properties

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.53.879

Isolation and structure of combretastatin

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.1139/V82-202

Identifiers

DOI

10.1517/13543776.2014.859247

1 reference

30 August 2017

1 reference